Cancer treatment, reimagined.
A clinical-stage, non-toxic therapy that destroys solid tumor cells from the inside out. No chemotherapy. No radiation. No collateral damage to healthy tissue.
How Targeted Osmotic Lysis works.
Solid tumor cells over-express a specific protein that normal cells do not. TOL exploits that single biological difference to selectively rupture cancer cells while leaving healthy tissue intact.
Target the channel.
Solid tumor cells over-express voltage-gated sodium channels on their cell membranes. Healthy adult cells do not. This is the biological signature TOL uses to find cancer.
Open the gate.
A precisely dosed channel activator opens those sodium channels in cancer cells. Sodium and water rush in. The membrane potential of healthy cells is undisturbed.
Block the pump.
A second agent inhibits the sodium-potassium pump cancer cells would use to recover. The cell cannot expel the sodium. Osmotic pressure climbs.
Rupture the cell.
Water continues to enter until the cancer cell physically bursts. The tumor mass shrinks. Healthy tissue is unharmed. No chemotherapy. No radiation. No surgery required.
A different kind of cancer therapy.
Conventional chemotherapy kills any rapidly dividing cell. TOL only affects cells with the wrong electrical profile. The result is a treatment that targets cancer at the level of cell physics, not cell biology.
Why solid tumors.
Carcinomas, sarcomas, and other solid tumor cancers over-express voltage-gated sodium channels as part of how they grow, invade, and metastasize. This over-expression is the same property TOL turns against them. The biological lock and the therapeutic key are the same molecule.
Why not blood or bone cancers.
Hematologic cancers such as leukemias and lymphomas, and primary bone marrow cancers, do not share this voltage-gated sodium channel signature in the same way. TOL is not designed for these conditions. Patients with these diagnoses should pursue standard hematology-oncology pathways.
Why non-toxic.
Both agents in the TOL combination are pharmacologically familiar molecules at the doses used. There is no cytotoxic chemotherapy in the regimen. Patients do not experience the alopecia, neutropenia, severe nausea, and immune suppression typical of conventional cancer treatment. Quality of life during treatment is preserved.
Where TOL fits in the current standard of care.
TOL is not positioned as a first-line replacement for surgery or curative-intent therapy in early-stage disease. It is positioned for patients with stage 3 and stage 4 solid tumor cancers who have exhausted, are refractory to, or wish to avoid conventional systemic chemotherapy. It can be considered alongside immunotherapy, targeted therapy, and supportive care depending on the case.
Built for advanced solid tumor cancers.
TOL is designed for a specific population. The cleaner the match, the better the candidacy.
Strong candidates
- Stage 3 or stage 4 solid tumor diagnosis
- Carcinomas (breast, lung, prostate, colorectal, pancreatic, ovarian, gastric, head and neck)
- Soft tissue sarcomas
- Patients refractory to standard chemotherapy
- Patients seeking non-toxic alternatives
- Patients wishing to preserve quality of life
Not a candidate
- Leukemias and lymphomas (hematologic)
- Multiple myeloma
- Primary bone marrow cancers
- Early-stage cancers curable by surgery
- Patients without confirmed tissue diagnosis
Available through partner clinics in three countries. Expanding.
TOL is administered by trained clinicians at vetted partner sites. New international locations are added on a rolling basis.
United States
Partner clinical sites accepting referrals.
Mexico
Active treatment centers, English-language support.
Australia
Partner clinic operating under local frameworks.
Expanding
New partner sites under evaluation. Ask in your consultation.
Backed by a decade of peer-reviewed research.
The mechanism, the molecules, and the selectivity of Targeted Osmotic Lysis have been characterized across multiple independent investigations in peer-reviewed scientific literature.
Voltage-gated sodium channels as a selective cancer target.
Peer-reviewed mechanistic work characterizing differential channel expression in solid tumor cell lines versus healthy tissue, and demonstrating selective osmotic lysis under TOL conditions.
View publication →Dose-response and selectivity in cancer cell models.
Pharmacodynamic and pharmacokinetic characterization of the TOL combination across solid tumor models, with selectivity ratios distinguishing malignant from normal cells.
View publication →Veterinary clinical translation in companion animals.
Naturally occurring cancers in companion animals treated under veterinary clinical protocols, demonstrating tumor response and tolerability of TOL administration in a translational setting.
View publication →Conference proceedings, American Association for Cancer Research.
Abstracts and proceedings presenting TOL mechanistic and pre-clinical data at major oncology research conferences.
View proceedings →Journal of Pharmacology and Experimental Therapeutics.
Original research and recent updates on TOL pharmacology, channel activation kinetics, and combination dosing.
View publication →Search the full literature on Targeted Osmotic Lysis.
The complete published record is indexed in PubMed and available for review by patients, physicians, and oncology consultants.
Search PubMed →Backed by three decades in FDA-regulated healthcare.
FixCancer.org is a patient-navigation initiative supported by Hillman Ventures, a Dallas-based private family office investing in FDA-regulated frontier biotech for over thirty years.
Regulatory rigor.
Every partner clinic, every consent document, every voluntary disclosure is reviewed against current FDA frameworks and the regulatory authority of the host country. Compliance is the floor, not the ceiling.
Patient-first navigation.
No commercial sale of unapproved drugs takes place through this site. Consultation routes patients to licensed treating physicians who independently evaluate eligibility, indication, and clinical appropriateness.
Long-horizon biotech.
Hillman Ventures invests in frontier biotech where the science is real, the regulatory pathway is defensible, and operators can absorb agency guidance at the cadence the science requires. TOL fits that thesis.
Full transparency on regulatory status.
Targeted Osmotic Lysis is an investigational therapy. The following voluntary disclosures explain its current standing with the United States Food and Drug Administration and with the regulatory authorities of every jurisdiction where partner clinics operate.
Investigational. Not FDA-approved.
Targeted Osmotic Lysis has not been approved by the U.S. Food and Drug Administration for the treatment of any disease. The therapy is investigational in the United States. Statements on this site regarding TOL have not been evaluated by FDA. Nothing on this site is intended to diagnose, treat, cure, or prevent any disease outside of an authorized investigational, expanded access, or right-to-try setting.
Expanded Access (Compassionate Use).
U.S. patients with serious or immediately life-threatening solid tumor cancers who have exhausted comparable or satisfactory alternative therapies may be eligible to receive TOL under FDA's Expanded Access program, governed by 21 CFR 312.300 through 312.320. Expanded Access requires the treating physician to submit a request to FDA and to obtain Institutional Review Board concurrence. Eligibility and submission are coordinated by the clinical liaison and the treating physician.
Right to Try Act (2018).
The federal Right to Try Act provides an additional pathway for eligible patients to access investigational therapies that have completed FDA Phase 1 testing and are under active investigation. Eligibility requires a life-threatening diagnosis, exhaustion of approved options, inability to participate in a clinical trial, and informed consent. The treating physician determines whether a patient qualifies and whether TOL is a clinically appropriate option under the Act.
ClinicalTrials.gov registration.
Active and completed clinical investigations of TOL are or will be registered on ClinicalTrials.gov in accordance with FDAAA 801 (Public Law 110-85) and 42 CFR Part 11. Patients and physicians are encouraged to review the public registration of any TOL-related study before electing treatment. Trial sponsors and principal investigators are disclosed there.
21 CFR Part 50.
All TOL administration occurs under written informed consent that complies with 21 CFR Part 50. The consent document discloses the investigational status of the therapy, the reasonably foreseeable risks and benefits, the alternatives to participation including no treatment, and the right to withdraw at any time without penalty to the patient's medical care.
Voluntary MedWatch reporting.
Adverse events associated with TOL administration in the United States are reported to FDA through the MedWatch program. Patients, caregivers, and clinicians are encouraged to report any suspected adverse reaction at fda.gov/medwatch. Voluntary post-market surveillance strengthens the safety profile of investigational therapies and protects future patients.
Mexico, Australia, and other jurisdictions.
TOL administered outside the United States operates under the regulatory framework of the host country. In Mexico, the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) governs medical therapy authorization. In Australia, the Therapeutic Goods Administration (TGA) operates the Special Access Scheme and Authorised Prescriber pathway for investigational treatments. Partner clinics in each jurisdiction operate in compliance with the applicable local authority. International administration does not constitute FDA endorsement.
Information, not promotion.
This website is intended as educational information for patients, caregivers, and clinicians. It is not a promotion, advertisement, or solicitation to purchase an unapproved drug or biologic in the United States. No commercial sale of TOL takes place through this site. Consultation requests are routed to licensed physicians who independently evaluate eligibility, indication, and appropriateness of care.
Treatment decisions belong with your physician.
No information on this site replaces the judgment of a licensed treating oncologist or primary physician. Patients should never discontinue, delay, or alter standard cancer therapy based on information from this website without first consulting their treating physician. The clinical liaison facilitates eligibility evaluation. The treating physician at the partner site makes all medical decisions.
Standing voluntary disclosure statement.
These statements have not been evaluated by the U.S. Food and Drug Administration. Targeted Osmotic Lysis is not approved by FDA for the diagnosis, treatment, cure, mitigation, or prevention of any disease. References to peer-reviewed scientific literature, conference proceedings, veterinary studies, and pre-clinical research do not constitute claims of clinical efficacy in human patients. Outcomes vary. No medical outcome is guaranteed by any source on this website, by any partner clinic, or by any clinician affiliated with this program.
FixCancer.org operates as an informational and patient-navigation resource. It is not a drug sponsor, manufacturer, distributor, or marketer. It does not sell, ship, or dispense any pharmaceutical product. All medical care occurs at independent licensed clinical sites under the jurisdiction of the appropriate medical authority. Patients retain the absolute right to discontinue consideration of TOL at any point, to seek second opinions, and to pursue any other medically appropriate option without consequence to their continued standard care.
Request a confidential consultation.
Tell us about the diagnosis. A clinical liaison reviews each inquiry, confirms eligibility, and connects qualified patients to the nearest active partner clinic. There is no cost to inquire.
What patients and families ask.
The most common questions during a first consultation.
Is Targeted Osmotic Lysis FDA-approved?
No. TOL is investigational. It is not approved by the U.S. Food and Drug Administration for the treatment of any disease. U.S. patients access TOL through FDA's Expanded Access program (21 CFR 312.300 through 312.320), the federal Right to Try Act (Public Law 115-176), or a registered clinical investigation. Outside the United States, partner clinics operate under the regulatory authority of the host country, including COFEPRIS (Mexico) and the Therapeutic Goods Administration (Australia). The full voluntary FDA disclosure is in the FDA Status section above.
Will I still need chemotherapy?
TOL is not chemotherapy. For some patients, TOL is used as a primary systemic therapy. For others, it is used alongside or after other modalities. The recommendation depends on the diagnosis, prior treatment history, and goals of care, and is made by the treating physician at the partner site.
What are the side effects?
The TOL regimen avoids the cytotoxic side effect profile of conventional chemotherapy. Specific adverse event profiles are reviewed during the consultation and are based on the clinical literature and partner-site experience. All medical therapy carries risk. There is no risk-free cancer treatment.
How long does treatment take?
Treatment courses are individualized. A typical course is administered over a period of weeks under physician supervision at the partner site. Travel and accommodation logistics are coordinated by the clinical liaison if treatment requires travel.
What does it cost?
Cost varies by partner site, country, and the specific protocol. The consultation itself is free. A treatment estimate is provided after eligibility is confirmed and the treating physician has reviewed the case.
My cancer is in my bones or blood. Can TOL help?
TOL is designed for solid tumor cancers that over-express voltage-gated sodium channels. Hematologic cancers, primary bone marrow cancers, and many bone-origin malignancies do not share this profile, and TOL is not indicated for these patients. Patients with these diagnoses should pursue standard hematology-oncology care.
How do I get started?
Submit the consultation form above. A clinical liaison will reach out within one business day to review the case and outline next steps.